Novartis is cleaning house, cutting its Huntington’s disease program along with several others. The company announced multiple program stops and delays in its full-year 2022 report Wednesday.
Tag Archive for: Piqray
A separation of Sandoz via a 100 percent spin-off will create the leading European generics company and a global leader in biosimilars, and a more focused Novartis.
